🔖
Bu Makaleye Atıf Yap
ABALI, O., BOZKURT, H., AYAYDIN, H. (2022). Letter to editor. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 4, 447–448. https://ajindex.com/articles/574253
Dergiler / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 4
Letter to editor
- Sayfa
- 447–448
- Yayın Tarihi
- 2022-10-17
- DOI
- —
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗Kaynakça (7)
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Ed). Text Revision Washington, DC: American Psychiatric Association; 2000
- Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302-381, 2002
- Lawer CP, Prioleau C, Lewis MM, et al. Intercations of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 612-27, 1999
- Bubl E, Perlov E, Tebartz Van Eltz L. Aripiprazole in patients with Tourette syndrome. World J. Bio. Psychiatry 7: 123-125, 2006
- Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum. Psychopharmacology 21: 447-453, 2006
- Miranda C M, Castiglioni T C. Aripiprazole for the treatment of Tourette syndrome, Experience in 10 patients. Rev. Med. Chil. 135: 773-778, 2007
- Stenstrom AD, Sindo I. Aripiprazole for the treatment of Tourette's syndrome. Ugeskr. Laeger. 170: 58, 2008.